OncoSec Medical Inc.
200 South Virginia Street
313 articles with OncoSec Medical Inc.
Compelling Data from Multiple Clinical Trials Using Company's Biomarker Technology Support Novel Approach to Immune Resistance Mechanisms in Cancer
OncoSec Medical Incorporated and Emerge Health Pty have entered into a collaboration agreement commercializing OncoSec's proprietary TAVO and making it available under Australia's Special Access Scheme in 2019.
OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility
Company Now Has Cash In Excess of $30 Million, Extending Cash Runway For At Least 12 Months
UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer
First-of-its-kind study seeking to evaluate the potential anti-tumor effect of the IL-12, IDO1 and anti-PD-1 triple combination
The Warrants will have an exercise price of $3.45, will be exercisable upon issuance and will expire five years from the date of issuance.
OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer
50% of Evaluated Patients Experienced a 20% or Greater Tumor Reduction
OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries
IL-12 has emerged as an important pro-inflammatory signaling cytokine, which many other companies are now using to develop cancer immunotherapies with several different modalities.
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that it intends to offer for sale a combination of shares of its common stock and warrants in an underwritten public offering.
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of its common stock
OncoSec Medical Incorporated announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the ThinkEquity Conference 2019 on Thursday, May 2, 2019, at 11:30 a.m. ET in New York, NY.
OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer
Triple combination seeks to improve upon the low historical anti-PD1 monotherapy durable remissions response rate of 13-16%
OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Duke University School of Medicine, today announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec's proprietary TAVO
Company Published White Paper titled, "Parachuting Behind Enemy Lines: OncoSec's Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)"
OncoSec Medical Incorporated announced that Dan O'Connor, President, Director & Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019, at 2:10 p.m. GMT / 10:10 a.m. EDT in London, United Kingdom.
OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, provided an update on recent pipeline and regulatory progress during a Key Opinion Leader (KOL) Symposium focused on the potential of TAVO™ (IL-12 / tavokinogene telseplasmid) on Friday, April 5, 2019 in New York City.
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO™ in Refractory Metastatic Melanoma
Classification as an ATMP Positions TAVO for Accelerated Review and Approval in Europe
OncoSec Medical Incorporated announced that management will present in the 31st Annual ROTH Conference taking place March 17-19, 2019 in Dana Point, CA.
OncoSec Announces Poster Presentation at 2019 American Association for Cancer Research Annual Meeting
Data Supports New Product Candidate's Ability To Elicit Robust Anti-Tumor Activity
OncoSec Medical Incorporated announced that Dan O'Connor, President, Director & Chief Executive Officer, will present a company overview at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 9:00 a.m. ET in New York, NY.
-- Company Will Provide a KEYNOTE-695 Update, an Overview of its Registrational-Enabled Cervical Cancer Study and Key 2019 Milestones